Jason Baum

Company: Leap Therapeutics

Job title: Vice President, Translational Medicine

Seminars:

Tumoral DKK1 as a Predictor of Outcomes and Response to DKN-01 3:50 pm

• DKK1 is overexpressed in many cancers, often leading to worse outcomes by promoting cancer cell proliferation, metastasis and angiogenesis • DKN-01 as a monotherapy and in combination has demonstrated compelling clinical data in multiple indications including gastroesophageal cancer, with enhanced responses seen in DKK1-high patients • DKK1 CDx development to support the clinical development…Read more

day: Day 1 - PM - red